Privium Fund Management B.V. Reduces Holdings in uniQure N.V. $QURE

Privium Fund Management B.V. reduced its stake in shares of uniQure N.V. (NASDAQ:QURE) by 22.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 447,486 shares of the biotechnology company’s stock after selling 131,653 shares during the period. uniQure accounts for about 1.4% of Privium Fund Management B.V.’s holdings, making the stock its 13th biggest position. Privium Fund Management B.V.’s holdings in uniQure were worth $6,260,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Aberdeen Group plc increased its position in uniQure by 24.2% during the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock worth $38,345,000 after buying an additional 535,163 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of uniQure during the second quarter valued at $117,000. Woodline Partners LP boosted its stake in shares of uniQure by 25.0% during the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after acquiring an additional 35,175 shares during the last quarter. 683 Capital Management LLC increased its position in uniQure by 1.6% during the 1st quarter. 683 Capital Management LLC now owns 1,550,000 shares of the biotechnology company’s stock worth $16,430,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Vestal Point Capital LP raised its stake in uniQure by 58.4% in the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock valued at $50,801,000 after purchasing an additional 1,767,572 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 226,316 shares of the business’s stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the completion of the sale, the chief executive officer owned 651,454 shares in the company, valued at approximately $27,009,282.84. The trade was a 25.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christian Klemt sold 15,000 shares of the stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00. Following the sale, the chief financial officer directly owned 217,730 shares of the company’s stock, valued at approximately $11,975,150. This trade represents a 6.45% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 244,316 shares of company stock valued at $10,328,181. 4.79% of the stock is owned by company insiders.

uniQure Price Performance

uniQure stock opened at $63.92 on Tuesday. uniQure N.V. has a 1 year low of $5.35 and a 1 year high of $65.14. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. The firm has a 50 day moving average price of $31.77 and a 200 day moving average price of $20.10. The company has a market cap of $3.51 billion, a price-to-earnings ratio of -16.31 and a beta of 0.56.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The company had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. Sell-side analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on QURE shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, October 8th. Royal Bank Of Canada reissued an “outperform” rating on shares of uniQure in a research note on Wednesday, September 24th. The Goldman Sachs Group raised their target price on shares of uniQure from $13.00 to $56.00 and gave the stock a “neutral” rating in a research report on Thursday, September 25th. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. Finally, Mizuho increased their price target on uniQure from $30.00 to $60.00 and gave the stock an “outperform” rating in a research note on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and an average target price of $71.75.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.